WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 27-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 33'7631 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 46'122  46'260  46'455  46'637  46'708  40'750  39'192  37'705 
Births 413  421  431  441  452  401  403  584 
Surviving infants 412  420  430  440  451  400  400  576 
Pop. less than 5 years 2'144  2'212  2'298  2'381  2'436  1'886  2'104  3'174 
Pop. less than 15 years 6'864  6'880  6'901  6'909  6'880  6'019  7'839  9'774 
Female 15-49 years 10'540  10'727  10'925  11'119  11'289  10'577  9'789  8'989 

Number of reported cases

(Click for retrospective incidence data for Spain)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  37  154  131  1'204  3'802  152  21'650  145'322 
Mumps
ChartChart
  13'951  9'539  4'416  9'391 
Pertussis
ChartChart
  2'342  3'439  3'088  921  10'075 
Polio*
ChartChart
  17 
Rubella
ChartChart
  64  30  345 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
  13  12  27  54  500 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Spain)
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          97  97  96  97  97  95  86 
DTP4          95  95 
IPV1         
HepB_BD         
HepB3          97  96  95  96  97  77 
Hib3          97  97  96  97  97  92 
JapEnc         
MCV1          96  96  95  97  97  94  99 
MCV2          95  93  91  90  91 
PCV1         
PCV3         
Pol3          97  97  96  97  97  95  94 
Rota1         
RotaC         
Rubella1          96  96  95  97 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Spain)
DTP1
ChartChart
  99  98  99  99  98  95 
DTP3
ChartChart
  97  96  97  97  95  86 
HepB3
ChartChart
  96  95  96  97  77 
HepB_BD
ChartChart
 
Hib3
ChartChart
  96  96  97  97  92 
MCV1
ChartChart
  96  95  97  97  94  99 
MCV2
ChartChart
  93  91  90  91 
PCV3
ChartChart
 
Pol3
ChartChart
  97  96  97  97  95  94 
RotaC
ChartChart
 

Number of districts in the country 19  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 6 months; Yes
DTaPHibIPV 4, 18 months; Yes
HPV 12 years (x2); Yes girls
HepA Yes risk groups
HepB_Adult Yes risk groups
HepB_Pediatric birth; Yes
Influenza_Adult >= 65 years; Yes and pregnant women, health care workers, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12 months; 3-4 years; Yes
MenC_conj 2,12 months;12 years; Yes
Pneumo_conj Yes From 2016
Pneumo_ps > 64 years; Yes and risk groups
Td 14 years; Yes
Tdap 6 years; Yes and pregnant women
Varicella 12 years (x2); Yes susceptible adolescents only and universal at M15 and Y3-Y4 from 2016
YF travelers

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  NA  NA  NA  NA  NA  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 19  19  19  19  19  19  19 
Nº districts with DTP3 coverage >=80% number 19  19  19  17  18  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  89  95  79  79 
Nº districts with measles (MCV1) coverage >=95% number 16  15  15  15  16  15  15 
% of districts with MCV1 coverage >=95% From 0 to 100% 84  79  79  79  84  79  79 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%       100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.